Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 20 2023 - 4:32PM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number: 001-39137
AnPac Bio-Medical
Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
INFORMATION CONTAINED IN THIS FORM 6-K
REPORT
Changes with respect to Registrant’s Certifying Accountant
AnPac Bio-Medical
Science Co., Ltd. (the “Company”) was notified by Friedman LLP (“Friedman”), the Company’s then
independent registered public accounting firm, that effective September 1, 2022, Friedman combined with Marcum LLP and continued
to operate as an independent registered public accounting firm. Friedman continued to serve as the Company’s independent registered
public accounting firm through January 11, 2023. On January 12, 2023, the audit
committee of the board of directors of the Company approved the engagement of Marcum Asia CPAs LLP (“Marcum Asia”) to serve
as the independent registered public accounting firm of the Company. The services previously provided by Friedman are now provided by
Marcum Asia.
Friedman’s
reports on the consolidated financial statements of the Company for the fiscal years ended December 31, 2021 and 2020 did not contain
any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, scope of accounting principles, except
that such reports expressed doubt regarding the Company’s ability to continue as a going concern. Furthermore, during the Company’s
two most recent fiscal years and through January 12, 2023, there were no disagreements with Friedman on any matters of accounting
principles or practices, financial statement disclosure or auditing scope which, if not resolved to the satisfaction of Friedman, would
have caused Friedman to make reference to such matters in their reports.
For
the fiscal years ended December 31, 2021 and 2020 and through January 12, 2023, except for the material weaknesses in internal
control reported by management in Item 15 of the Company’s Form 20-F filed with U.S. Securities and Exchange Commission (the
“SEC”) on May 16, 2022, there were no other reportable events (as that term is described in Item 304(a)(1)(v) of
Regulation S-K).
The Company
provided Friedman with a copy of the forgoing disclosure and requested Friedman to furnish the Company with a letter addressed to the
SEC stating whether or not Friedman agrees with the above statements. A copy of Friedman’s letter, dated January 18,
2023, is filed as Exhibit 16.1 to this Form 6-K.
During the two most recent fiscal years and in the subsequent period
through January 12, 2023, the Company has not consulted with Marcum Asia with respect to the application of accounting principles
to a specified transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company’s
consolidated financial statements, or any other matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
AnPac Bio-Medical Science Co., Ltd. |
|
|
|
By: |
/s/Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
Co-Chief Executive Officer |
Dated: January 20,
2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2024 to May 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From May 2023 to May 2024